Browse Multiple sclerosis topic

Drug therapy subtopic

Articles 1-100 out of 100 article(s) Title Author Type Date Words LOVE-SPLIT M.S. WOMAN TOOK HER OWN LIFE; Deadly drugs cocktail killed Fernanda. Oct 23, 2009 334 Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data. Sep 11, 2009 2380 Data Supporting Unique Efficacy of TYSABRI Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Sep 11, 2009 1224 Fewer Injection Site Reactions in Patients Using AVONEX[R] Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis. Sep 11, 2009 902 Laquinimod Immunomodulatory Action Confers Both Neuroprotective and Anti-Inflammatory Properties. Sep 11, 2009 1726 Biogen Idec Showcases More Than 70 Data Presentations at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Sep 2, 2009 1882 Drug to help MS. Aug 24, 2009 207 Cheap BP drug could help treat multiple sclerosis. Aug 18, 2009 374 United States: Novartis gets FDA approval for MS drug. Aug 17, 2009 82 Research and Markets: Multiple Sclerosis Therapy Area Pipeline Report: Latest Company News and Drugs Analysis by Stage and Company. Report Aug 11, 2009 350 Diabetes drug may limit MS damage. Jul 28, 2009 124 FDA expands labeling for Copaxone. Brief article Jun 22, 2009 119 In the know: drug trial basics. Mofitt, Kevin Jun 22, 2009 496 In the pipeline: MS pills are moving from lab through clinical trials. Brief article Jun 22, 2009 236 Lower cost disease-modifying drugs? Cohen, Rose Jun 22, 2009 741 Identifying barriers to using an MS drug. Jun 22, 2009 494 Diabetes drug found to provide protective effects against multiple sclerosis. May 27, 2009 389 Oral drugs for Multiple Sclerosis may hit market in two years: MSSI. May 22, 2009 769 MS pill to be on market soon. Apr 30, 2009 192 New pill to replace painful multiple sclerosis jabs. Apr 30, 2009 309 New Data Illustrate Novel Mechanism of Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis. Clinical report Apr 28, 2009 1623 Research and Markets: Take Advantage of the Latest Opportunities for Oral Drugs within the Multiple Sclerosis Treatment Market. Mar 26, 2009 408 CAM: low-dose naltrexone (LDN): the "411" on LDN. Bowling, Allen C. Drug overview Mar 22, 2009 1016 Funding the movement: Goodyear generations come together. Hubler, Eric Mar 22, 2009 674 Fast Forward supports novel therapy for MS. Brief article Mar 22, 2009 309 Is a clinical trial right for you? Brief article Mar 22, 2009 240 COPAXONE[R] Approved by the FDA for Patients with a First Clinical Event Suggestive of Multiple Sclerosis. Mar 3, 2009 1230 Stepping up to the plate for MS research. Richert, John R. Report Dec 22, 2008 833 Tysabri: two new cases of PML--and a label change. Brief article Dec 22, 2008 143 High-dose regimen of cancer drug reduces MS disease activity. Dec 22, 2008 67 All that is green is not always good. Bowling, Allen C. Report Dec 22, 2008 862 Specialist's hopes for new MS drug. Oct 27, 2008 236 Opexa Provides Additional Promising Data Including Statistically Significant Reduction in Disability With Tovaxin(R) for the Treatment of Multiple Sclerosis. Oct 23, 2008 1854 WORLD TODAY: Drug may ease MS. Oct 23, 2008 124 Wonder drug in fight on MS; HEALTH: Leukaemia treatment may combat multiple sclerosis. Oct 23, 2008 352 MS drug gave me new hope; TEENAGER HAILS EFFECT OF TREATMENT. Oct 23, 2008 647 Cancer drug 'can make MS sufferers less disabled'. Oct 23, 2008 201 Funding the movement: Dr. Agnes Varis makes connections. King, Martha Sep 22, 2008 701 Study: Fampridine-SR speeds walking in all types of MS. Brief article Sep 22, 2008 70 Acorda Therapeutics Presents Additional Data from Second Positive Phase 3 Study of Fampridine-SR at World Congress on Treatment and Research in Multiple Sclerosis. Sep 20, 2008 1673 Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin(R) for the Treatment of Multiple Sclerosis. Sep 19, 2008 1959 Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis. Sep 18, 2008 1850 Acorda Therapeutics To Present Phase 3 Fampridine-SR Data at World Congress on Treatment and Research in Multiple Sclerosis Meeting. Sep 12, 2008 489 Top-Line Data from Opexa's Phase IIb Tovaxin(R) Study to be Presented at World Congress on Treatment and Research in Multiple Sclerosis. Sep 11, 2008 994 KEEP USING IT; Two MS patients taking drug hit by brain disease, but company urges.. Aug 2, 2008 323 Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis. Jul 22, 2008 1406 Teva & ANP Announce That ATL/TV1102, a Novel Drug for the Treatment of Relapsing Remitting Multiple Sclerosis (RRMS), Demonstrated Significant Reduction in Disease Activity. Clinical report Jun 29, 2008 1323 Study: one course of Rituximab reduced MS disease activity for 48 weeks. Brief article Jun 22, 2008 73 Tysabri in the news. Brief article Jun 22, 2008 225 Society publishes opinion paper on marijuana. Jun 22, 2008 406 BaroFold Inc. Initiates First Human Studies for Multiple Sclerosis Drug Candidate, BaroFeron(TM). Jun 16, 2008 555 New Data Show Treatment of Multiple Sclerosis (MS) with AVONEX(R) (interferon Beta-1a) Enhances Quality of Life. Clinical report Apr 16, 2008 702 Bayhill Therapeutics Announces Presentation of MS Drug Candidate BHT-3009 at American Academy of Neurology 60th Annual Meeting. Apr 11, 2008 508 Help from MS drug makers. Boerner, Heather Mar 22, 2008 988 Opexa Therapeutics Announces Completion of Mid Study Descriptive Analysis on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis. Mar 11, 2008 914 Cancer drug limits MS relapses. Seppa, Nathan Brief article Feb 23, 2008 243 Stanford Researchers Find Protein Targets for Potential Treatment of Multiple Sclerosis. Feb 17, 2008 861 National Multiple Sclerosis Society Launches Drug Development Initiative. Nov 27, 2007 629 Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the European Committee for Treatment and Research of Multiple Sclerosis. Oct 11, 2007 1447 New TYSABRI(R) Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis. Oct 11, 2007 1236 Accentia Announces Investigational New Drug Application for Revimmune Usage in a Pivotal Phase 3 Study of Refractory Multiple Sclerosis. Oct 8, 2007 1173 New Zealand boost for Elan's MS drug. Oct 1, 2007 89 Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis. Clinical report Sep 11, 2007 788 Drug to limit MS agony. Aug 3, 2007 84 Accentia Biopharmaceuticals Files Pre-Investigational New Drug (IND) Application with FDA for Pivotal Phase 3 Clinical Trial of Revimmune for Refractory Multiple Sclerosis. Jul 31, 2007 1818 Expert hits out over MS drug hitch. Jul 23, 2007 362 Warning over MS drug's delay. Jul 23, 2007 196 TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis. Jul 23, 2007 884 Setback for GW as European regulators stall over MS drug. Jul 20, 2007 95 Setback for GW as European regulators stall over MS drug. Jul 20, 2007 95 Setback for GW as European regulators stall over MS drug. Jul 20, 2007 95 Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of Multiple Sclerosis. Clinical report May 17, 2007 915 BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration on Biomarker Discovery for MS Disease Activity and Drug Response. May 16, 2007 682 Long-Term Data Demonstrated Significantly Better Patient Adherence to COPAXONE(R) versus Interferons in Multiple Sclerosis Treatment. Clinical report Oct 3, 2006 1038 Very Active Multiple Sclerosis Patients Benefited from COPAXONE(R) Treatment Following Short-Term Induction with Mitoxantrone. Sep 29, 2006 1294 New Study: AVONEX(R), The Most Prescribed Multiple Sclerosis Treatment Worldwide, Demonstrates Superior Adherence. Sep 28, 2006 959 New Data Confirmed Antibodies to COPAXONE(R) do not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis. Sep 28, 2006 1193 Commission to fund group of MS drugs. Sep 28, 2006 89 Weapon against MS: transplant drug limits nerve damage. Seppa, N. Sep 16, 2006 522 Study Showed Treatment with COPAXONE(R) is Associated with Significantly Fewer Days Missed from Work in Multiple Sclerosis Patients; Non-Treatment and Treatment with Avonex(R) or Betaseron(R) Had No Significant Impact on Days Missed. Sep 12, 2006 1071 Laquinimod Phase IIb Trial Confirms Efficacy and Favorable Safety Profile and Shows Significant Reduction in the Rate of Inflammatory Disease Activity. Sep 5, 2006 1038 First Patient Enrolled in Study to Evaluate Impact of Regular Neutralizing Antibody (NAb) Testing on Multiple Sclerosis Treatment Patterns. Aug 21, 2006 1026 Antigen-specific multiple sclerosis therapy to be evaluated. Mechcatie, Elizabeth Clinical report Aug 1, 2006 649 Biogen Idec and Elan Announce Availability of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis. Jul 24, 2006 1078 The MS 'miracle' DRUG HELPS SUFFERERS WALK AND SEE AGAIN. Jul 22, 2006 496 MY MS MIRACLE; Drug brings new life to sufferers of crippling disease. Jul 22, 2006 347 TYSABRI(R) Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis. Jun 29, 2006 397 In January, Rhode Island became the eleventh state to legalize medical marijuana, and its first resident to apply for a drug permit was a 43-year-old woman suffering from multiple sclerosis. Brief article May 8, 2006 100 CHMP Issues Positive Opinion for TYSABRI(R) as a Treatment for Relapsing-Remitting Multiple Sclerosis. Apr 28, 2006 539 MultiCell to Present Company's Lead Drug Candidates at Equities Magazine Investor Conference; President Dr. Chang to Present Novel Therapeutic Compounds to Treat Fatigue, Multiple Sclerosis, Diabetes and Other Diseases. Apr 20, 2006 727 MultiCell to Present Company's Portfolio of Novel Drug Candidates at BIO 2006 Conference; Company President Dr. Stephen Chang to Discuss Novel Therapeutic Candidates Targeting Multiple Sclerosis, Diabetes and Other Medical Needs. Apr 10, 2006 752 MS drug linked to one death in clinical trial. Wachter, Kerri Apr 1, 2006 179 Do over: new MS drug may be safe after all. Seppa, N. Mar 4, 2006 564 Chromos signs agreement with AppTec to manufacture multiple sclerosis drug. Mar 1, 2006 569 It is Believed that Natalizumab's Efficacy in the Treatment of Multiple Sclerosis Makes it Likely that the Agent Will Reenter the Market. Jan 27, 2006 564 Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Multiple Sclerosis. Jan 23, 2006 509 MultiCell Technologies In-Licenses Phase IIb/III Drug for the Treatment of Fatigue in Multiple Sclerosis from Amarin Corporation. Jan 3, 2006 988 Cognition and fatigue in multiple sclerosis: potential effects of medications with central nervous system activity. Oken, Barry S.; Flegal, Kristin; Zajdel, Daniel; Kishiyama, Shirley S.; Lovera, Jesus; Bagert, Bridg Clinical report Jan 1, 2006 5564 Scientists Demonstrate Investigational MS Drug Down Regulates the Underlying Cause Believed Responsible for Multiple Sclerosis. Dec 19, 2005 711 Cannabis MS drug approved. Nov 16, 2005 250